KNTE
Price:
$2.65
Market Cap:
$124.99M
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinna...[Read more]
Industry
Biotechnology
IPO Date
2020-12-03
Stock Exchange
NASDAQ
Ticker
KNTE
According to Kinnate Biopharma Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 13.19. This represents a change of 11.64% compared to the average of 11.81 of the last 4 quarters.
The mean historical Current Ratio of Kinnate Biopharma Inc. over the last ten years is 26.57. The current 13.19 Current Ratio has changed 4.86% with respect to the historical average. Over the past ten years (40 quarters), KNTE's Current Ratio was at its highest in in the December 2020 quarter at 54.79. The Current Ratio was at its lowest in in the March 2020 quarter at 0.
Average
26.57
Median
19.09
Minimum
13.19
Maximum
54.79
Discovering the peaks and valleys of Kinnate Biopharma Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 130.24%
Maximum Annual Current Ratio = 54.79
Minimum Annual Increase = -61.89%
Minimum Annual Current Ratio = 13.19
Year | Current Ratio | Change |
---|---|---|
2023 | 13.19 | -1.93% |
2022 | 13.45 | -35.61% |
2021 | 20.88 | -61.89% |
2020 | 54.79 | 37.60% |
2019 | 39.82 | 130.24% |
The current Current Ratio of Kinnate Biopharma Inc. (KNTE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
15.84
5-year avg
28.43
10-year avg
26.57
Kinnate Biopharma Inc.’s Current Ratio is greater than Ambrx Biopharma Inc. (12.80), greater than Acelyrin, Inc. (7.86), greater than Windtree Therapeutics, Inc. (0.23), greater than Palisade Bio, Inc. (4.31), greater than Century Therapeutics, Inc. (10.62), greater than Passage Bio, Inc. (7.67), greater than Homology Medicines, Inc. (4.19), greater than Generation Bio Co. (7.42), greater than Stoke Therapeutics, Inc. (6.67), greater than Gracell Biotechnologies Inc. (7.73), less than Theseus Pharmaceuticals, Inc. (29.93), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), less than Erasca, Inc. (16.79), greater than Kronos Bio, Inc. (8.49), greater than C4 Therapeutics, Inc. (5.09), less than Edgewise Therapeutics, Inc. (30.24), greater than Surrozen, Inc. (6.96), greater than Bolt Biotherapeutics, Inc. (4.28), greater than Larimar Therapeutics, Inc. (10.93), less than Keros Therapeutics, Inc. (20.37), greater than Kezar Life Sciences, Inc. (9.58),
Company | Current Ratio | Market cap |
---|---|---|
12.80 | $1.77B | |
7.86 | $423.19M | |
0.23 | $1.66M | |
4.31 | $4.25M | |
10.62 | $123.69M | |
7.67 | $43.48M | |
4.19 | $3.02M | |
7.42 | $145.50M | |
6.67 | $773.92M | |
7.73 | $989.87M | |
29.93 | $181.50M | |
6.56 | $349.21M | |
41.42 | $264.42M | |
16.79 | $807.96M | |
8.49 | $59.36M | |
5.09 | $374.42M | |
30.24 | $1.64B | |
6.96 | $29.60M | |
4.28 | $24.78M | |
10.93 | $513.64M | |
20.37 | $1.97B | |
9.58 | $40.82M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kinnate Biopharma Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kinnate Biopharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Kinnate Biopharma Inc.'s Current Ratio?
How is the Current Ratio calculated for Kinnate Biopharma Inc. (KNTE)?
What is the highest Current Ratio for Kinnate Biopharma Inc. (KNTE)?
What is the 3-year average Current Ratio for Kinnate Biopharma Inc. (KNTE)?
What is the 5-year average Current Ratio for Kinnate Biopharma Inc. (KNTE)?
How does the current Current Ratio for Kinnate Biopharma Inc. (KNTE) compare to its historical average?